Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients.

IF 2.4
Crystal Watson, Arie Barlev, Jodie Worrall, Steve Duff, Rachel Beckerman
{"title":"Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients.","authors":"Crystal Watson,&nbsp;Arie Barlev,&nbsp;Jodie Worrall,&nbsp;Steve Duff,&nbsp;Rachel Beckerman","doi":"10.1080/21556660.2020.1854561","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic burden of CHOP-associated adverse events (AEs) in PTLD patients. Since PTLD is rare, searches included lymphoproliferative disease with lymphoma patients.</p><p><strong>Design: </strong>This comprehensive literature review used the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) protocol, pre-specifying the search strategy and criteria. CHOP-associated short-term AEs with an incidence of >4% were sourced from published literature and cancer websites to inform the search strategy. PubMed and EMBASE searches were used to identify humanistic and economic burden studies.</p><p><strong>Results: </strong>PubMed and EMBASE searches identified 3946 citations with 27 lymphoma studies included. Studies were methodologically heterogeneous. Febrile neutropenia (FN) was the AE most encountered, followed by chemotherapy-induced (CI) anemia (A), infection, CI-nausea and vomiting, thrombocytopenia, and CI-peripheral neuropathy (PN). FN and infections were associated with significant disutility, increased hospitalization, and extended length of stay (LOS). Infections and CIPN significantly impacted the utility of patients and CIA-related fatigue showed reductions in quality of life (QoL). Many patients continue to have QoL deficits continued even after AEs were treated. Management costs varied greatly, ranging from nominal (CIPN) to over $100,000 in the USA for infections, EUR 10,290 in Europe for infections, or CAN$1012 in Canada for FN. Cost of outpatient care varied but had a lower economic impact compared to hospitalizations.</p><p><strong>Conclusions: </strong>Short-term AEs from CHOP in the lymphoma population were associated with substantial humanistic and economic burden.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2020-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21556660.2020.1854561","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21556660.2020.1854561","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Purpose: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic burden of CHOP-associated adverse events (AEs) in PTLD patients. Since PTLD is rare, searches included lymphoproliferative disease with lymphoma patients.

Design: This comprehensive literature review used the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) protocol, pre-specifying the search strategy and criteria. CHOP-associated short-term AEs with an incidence of >4% were sourced from published literature and cancer websites to inform the search strategy. PubMed and EMBASE searches were used to identify humanistic and economic burden studies.

Results: PubMed and EMBASE searches identified 3946 citations with 27 lymphoma studies included. Studies were methodologically heterogeneous. Febrile neutropenia (FN) was the AE most encountered, followed by chemotherapy-induced (CI) anemia (A), infection, CI-nausea and vomiting, thrombocytopenia, and CI-peripheral neuropathy (PN). FN and infections were associated with significant disutility, increased hospitalization, and extended length of stay (LOS). Infections and CIPN significantly impacted the utility of patients and CIA-related fatigue showed reductions in quality of life (QoL). Many patients continue to have QoL deficits continued even after AEs were treated. Management costs varied greatly, ranging from nominal (CIPN) to over $100,000 in the USA for infections, EUR 10,290 in Europe for infections, or CAN$1012 in Canada for FN. Cost of outpatient care varied but had a lower economic impact compared to hospitalizations.

Conclusions: Short-term AEs from CHOP in the lymphoma population were associated with substantial humanistic and economic burden.

Abstract Image

Abstract Image

探讨移植后淋巴增生性疾病短期CHOP化疗不良事件的负担:淋巴瘤患者的综合文献综述。
目的:环磷酰胺、阿霉素、长春新碱、强的松(CHOP)是一种治疗利妥昔单抗(一种侵袭性和潜在致命的淋巴瘤)失败后实体器官移植(SOT)后移植后淋巴细胞增生性疾病(PTLD)的方法。本研究探讨了PTLD患者chop相关不良事件(ae)的人文和经济负担。由于PTLD是罕见的,搜索包括淋巴增生性疾病淋巴瘤患者。设计:本综合文献综述采用系统评价和荟萃分析首选报告项目(PRISMA)方案,预先指定检索策略和标准。发生率>4%的chop相关短期不良事件来源于已发表的文献和癌症网站,以告知搜索策略。PubMed和EMBASE检索用于确定人文和经济负担研究。结果:PubMed和EMBASE检索确定了3946条引用,包括27项淋巴瘤研究。研究在方法学上是异质的。发热性中性粒细胞减少症(FN)是最常见的AE,其次是化疗性贫血(A)、感染、CI-恶心和呕吐、血小板减少症和CI-周围神经病变(PN)。FN和感染与显著的负效用、住院增加和住院时间延长(LOS)相关。感染和CIPN显著影响患者的效用,cia相关疲劳显示生活质量(QoL)下降。许多患者即使在不良事件治疗后仍然存在生活质量下降。管理费用差异很大,从名义(CIPN)到美国感染的10万美元以上,欧洲感染的10290欧元,加拿大FN的1012加元不等。门诊治疗的费用各不相同,但与住院治疗相比,其经济影响较小。结论:在淋巴瘤人群中,CHOP的短期不良事件与巨大的人文和经济负担相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Drug Assessment
Journal of Drug Assessment PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信